Patents Examined by Christine J. Saoud
  • Long-acting VEGF inhibitors for intraocular neovascularization
    Patent number: 11382955
    Abstract: Compositions and methods for treating a VEGF-related ophthalmic disorder in a subject in need comprising, administering intravitreally to the subject a therapeutically effective amount of an anti-VEGF agent, comprising a VEGF binding portion operatively linked to a Fc-IgG, wherein the VEGF binding portion comprises at least one VEGF binding domain that is an IgG-like domain 2 of VEGFR-1.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: July 12, 2022
    Assignee: The Regents of the University of California
    Inventor: Napoleone Ferrara
  • Dual-targeting antibody targeting SCF and galectin-1 and use thereof
    Patent number: 11377489
    Abstract: The present invention relates to a dual-targeting antibody targeting stem cell factor (SCF) and galectin-1 and a composition for preventing or treating angiogenesis-related diseases comprising the same. The present invention provides a dual-targeting antibody derived from a human monoclonal antibody which may effectively inhibit angiogenesis by simultaneously neutralizing SCF and galectin-1 involved in angiogenesis, and a pharmaceutical composition for preventing or treating angiogenesis-related diseases comprising the antibody. The dual-targeting antibody according to the present invention may effectively prevent or treat angiogenesis-related diseases by simultaneously neutralizing two targets involved in angiogenesis wherein the angiogenesis-related diseases cause hemorrhaging by blood vessels changing due to abnormal angiogenesis and thus increasing the permeability thereof.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: July 5, 2022
    Assignee: NOVELTY NOBILITY INC.
    Inventor: Sang Gyu Park
  • Methods of treating inflammation with monomeric CXCL12 peptide
    Patent number: 11369662
    Abstract: The present invention provides a CXCL121 peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: June 28, 2022
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: Brian Volkman, Joshua Ziarek, Christopher Veldkamp, Francis Peterson
  • Mutant FGF21 polypeptide compositions
    Patent number: 11365228
    Abstract: The present invention relates, in one aspect, to certain mutant FGF21 polypeptide constructs. In certain non-limiting embodiments, the construct binds to ?-Klotho more tightly than wild-type FGF21. In certain non-limiting embodiments, the construct has a mutation in at least one residue of SEQ ID NO:3 selected from the group consisting of V188, R203, and L194. In certain non-limiting embodiments, the construct further comprises a stability enhancing domain.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: June 21, 2022
    Assignee: YALE UNIVERSITY
    Inventors: Joseph Schlessinger, Sangwon Lee
  • Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
    Patent number: 11364281
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: June 21, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • Method for improving resistance to breakage and eggshell strength
    Patent number: 11358996
    Abstract: Described herein are FGF-23 epitope peptides, methods of producing antibodies in laying hens by injecting the peptides, and methods of improving resistance to eggshell breakage and/or increasing eggshell strength by administering an FGF-23 epitope peptide to a laying hen.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: June 14, 2022
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Daniel Butz, Zhouzheng Ren, Alexis Jo Piepenburg, Mark Eric Cook
  • Methods of treating colorectal cancer
    Patent number: 11332529
    Abstract: This disclosure provides methods for treating a tumor derived from a colorectal cancer exhibiting a high degree of microsatellite instability in a subject comprising administering to the subject an anti-PD-1 antibody. In some embodiments, the method further comprises administering an anti-CTLA-4 antibody. In some embodiments, the colorectal cancer is rectal cancer, colon cancer, or any combination thereof.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: May 17, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventor: Michael Axelson
  • Use of FGF21 in methods of increasing exocrine pancreatic secretion
    Patent number: 11318186
    Abstract: The present invention relates to the treatment of secretory disorders, and provides novel methods of treatment of these disorders comprising the administration of fibroblast growth factor 21 (FGF21) or derivatives thereof. The methods of the invention are useful in conditions including exocrine pancreatic insufficiency (EPI), for example EPI resulting from cystic fibrosis, alcoholism, pancreatitis, pancreatic cancer, gallstones, celiac disease, high triglycerides, or lupus. The methods of the present invention find further utility in the treatment of salivary flow disorders, for example Sjorgen's syndrome, and the treatment of EPI or pancreatitis resulting from surgical procedures.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: May 3, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: David J. Mangelsdorf, Steven A. Kliewer, Katie C. Coate, Genaro Hernandez
  • Antibody directed against the endothelin receptor beta sub-type
    Patent number: 11312780
    Abstract: Antibodies directed against the endothelin receptor sub-type B, in particular monoclonal antibodies, a fragment or derivative thereof. The present disclosure also relates to the therapeutic, diagnostic use or as a research tool of such an antibody in the field of cancers and in particular glioblastoma.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: April 26, 2022
    Assignee: COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES
    Inventors: Didier Boquet, Frédéric Ducancel, Amaury Herbet, Narciso Costa, Jean-Philippe Hugnot
  • Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides
    Patent number: 11311605
    Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: April 26, 2022
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Method diagnosis of a prenatal disorder by selective determination of placental growth factor 2
    Patent number: 11307209
    Abstract: The present invention relates to an immunoassay method for placental growth factor 2 (PlGF-2) detection in pregnant subjects. Furthermore the invention relates to the use of said method for the diagnosis, prognosis, risk assessment and therapy control of prenatal disorders comprising the determination of the level of PlGF-2 in said pregnant subjects.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: April 19, 2022
    Assignee: CÉZANNE S.A.S.
    Inventors: Gaïané Demirdjian, Delphine Espinasse
  • Fusion protein containing TGF-? receptor and medicinal uses thereof
    Patent number: 11274142
    Abstract: The present invention provides a fusion protein containing TGF-? receptor and pharmaceutical use thereof. Further, the present invention provides a bifunctional fusion protein comprising the PD-L1 antibody targeting portion and the TGF-?RII extracellular domain, and a pharmaceutical composition comprising the fusion protein containing TGF-? receptor, and the use thereof in the preparation of anti-cancer drug.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: March 15, 2022
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jinming Gu, Xiao Luo, Weikang Tao
  • Compositions and methods for treating heart failure
    Patent number: 11253573
    Abstract: The present invention provides methods for treating chronic heart failure patients using the medication comprising neuregulin. The methods comprise first performing a companion diagnostic test of each patient before treatment; and then providing a suitable treatment to the patient according to the results of the companion diagnostic test. When the result of the test is within a favorite treatment zone, the patient is suitable for heart failure treatment by administering an effective amount of neuregulin.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: February 22, 2022
    Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.
    Inventor: Mingdong Zhou
  • Use of a VEGF antagonist to treat angiogenic eye disorders
    Patent number: 11253572
    Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: February 22, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventor: George Yancopoulos
  • Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides
    Patent number: 11248031
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: February 15, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Paul E. Morin, Daniel Cohen, Ranjan Mukherjee, Timothy P. Reilly, Rose C. Christian, Dasa Lipovsek, Ray Camphausen, John Krupinski
  • Neuregulin based methods for treating heart failure
    Patent number: 11246909
    Abstract: The present invention features methods of treating patients with chronic heart failure by administering a neuregulin polypeptide within a dosage range which is both effective and safe.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: February 15, 2022
    Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.
    Inventor: Mingdong Zhou
  • Antigen binding proteins that bind to a complex comprising ?-Klotho and an FGF receptor
    Patent number: 11248052
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing ?-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising ?-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: February 15, 2022
    Assignee: AMGEN INC.
    Inventors: Yang Li, Jennitte LeAnn Stevens, Chadwick Terence King, Ian Nevin Foltz, Gunasekaran Kannan, Junming Yie, Shaw-Fen Sylvia Hu
  • Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
    Patent number: 11241481
    Abstract: Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: February 8, 2022
    Assignee: NGM BIOPHARMACEUTICALS, INC.
    Inventors: Lei Ling, Hui Tian
  • Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
    Patent number: 11235031
    Abstract: The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: February 1, 2022
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Anindita Ganguly, Jennifer Iaci, Tom Parry
  • Human monoclonal antibodies specific for FLT3 and uses thereof
    Patent number: 11236171
    Abstract: Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: February 1, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Weizao Chen, Terry J. Fry, Christopher Chien, Haiying Qin